|
Pharma Mergers — The Keys to Survival in an Imploding World
2009 Program Agenda
Featured Speakers :
|
Karen Bernstein
Co-Founder, Chairman & Editor-in-Cheif
BioCentury
|
|
P. Reed Maurer
Chairman
aRigen Pharmaceuticals
|
|
Chris Cashman
President & CEO
Protez
|
|
Meryle Melnicoff
Director of Business Development
Wistar Institute
|
|
Steve Engen
President and Representative Director
Solasia
|
|
Atsushi Nagahisa
President and CEO
RaQualia Pharma, Inc
|
|
David Flores
Co-Founder, President & CEO
BioCentury
|
|
Ichiro Nakatomi
President and CEO
NanoCarrier Co., Ltd.
|
|
James Foley
Director
Japan America Society of Greater Philadelphia
|
|
Gregory Salathe
Co-Managing Partner
Morgan Lewis Tokyo
|
|
Koichi Kato
Senior Director
External Scientific Affairs
BANYU PHARMACEUTICAL CO., LTD
|
|
Charlotte Sibley
Senior Vice President
Corporate Business Services
Shire
Pharmaceuticals
|
|
Patrick Keohane
Head of R&D Japan
Astra Zeneca
|
|
Goro Takeda
Venture Partner
Sofinnova Ventures
|
|
David King
Venture Partner
Quaker BioVentures
|
|
Shinichi Tamura
President & CEO
Sosei
|
|
Kazuki Kusaka
Managing Director & COO
Lazard Freres K.K.
|
|
Kohei Ueda
GM of Strategic Research Planning
Takeda Pharmaceuticals
|
|
Tadashi Matsumoto
CEO & Founder
ReqMed
|
|
|
|
|
Program Overview |
The Pharmaceutical Pyramid
At the base are technologies, conceived of more and more often at universities and young biotechnology companies. As product development grows and becomes increasingly more expensive, these technologies move to large companies either through licensing or corporate acquisition. And, as the cost of R&D grows even more, the large companies are forced to merge, leaving only a few organizations at the tip of the pyramid. Where will Japanese pharma companies fit in this pyramid – in the middle, or at the top?
Have big mergers, creating ever larger pharma companies, delivered on their promises to add value? Or are smaller, more strategic ‘bolt on’ deals, which often result from a biotech/ pharma licensing or research collaboration a better answer? What do early stage biotech companies have to be today and what do they need to accomplish over the next few years to survive? The 10th Annual Philadelphia-Japan Health Sciences Dialogue will explore these phenomena in depth.
|
| |
|
Part One: Monday, November 9 - 9:30 a.m. - 5:30 p.m., Reception: 6:00 p.m. |
| |
Morning Sessions |
| 9:30 am |
Welcome and Introductions
|
| |
Dr. James Foley, Director, Japan America Society of Greater Philadelphia
Bonnie Grant, Executive Director, Greater Philadelphia Life Sciences Congress, Philadelphia Convention & Visitors Bureau
Kenji Okada, Kobe Life Science Cluster, Kobe City Government
|
| 10:00 am |
The Technology Transfer Edge
|
| |
Introduction
Taro Yaguchi, President, Japan Technology Group
“Induction of Spontaneous Articular Cartilage Tissue Regeneration by Using Double-Network Hydrogel,”
“A Novel Host-Oriented Mechanism For Viral Infection,”
Akio Hitoshio, Manager, International strategy, Patent Attorney,
Center for Innovation and Business Promotion, Hokkaido University
"Marine Natural Products Library"
Dr. Yoichi Nakao, Associate Professor, Faculty of Science and Engineering, Waseda University
“NAIST. Challenge to Medical Innovation from NARA and KANSAI,”
Naoki Tani, Professor、Industry-Government-Academia Collaboration, Nara Institute of Science and Technology (NAIST)
“Enhanced antibody production following DNA immunization with HMGB1- fused antigen,”
Tamotsu Niki, Coordinator, RIDAI SCITEC, Tokyo University of Science
“A New Generation of Oncolytic Virotherapy,”
Shiro Mita, Doctor of Pharmacology, Chairman M’s Science Corporation, Nagoya University
(click here for university details)
|
| 12:30 pm |
The Shire Lunch
|
| |
|
| |
Afternoon Sessions |
| 1:30 pm |
Technology Transfer in the US - Finding Opportunities During Challenging Times
|
| |
Meryle Melnicoff, Director of Business Development,
Wistar Institute, University of Pennsylvania
|
| 2:00 pm |
Building a Company Through Licensing
|
| |
Charlotte Sibley, Senior VP of Corporate Business Services
Business Management, Shire Pharmaceuticals
|
| 2:30 pm |
Biotech Venture Capital Panel—Financing Growth
|
| |
David King, Venture Partner, Quaker BioVentures
Goro Takeda, Venture Partner, Sofinnova Ventures
Tadashi Matsumoto, CEO & Founder, ReqMed
|
| 4:00 pm |
CEO Panel—Exit Strategies for Biotech Companies
|
| |
Karen Bernstein, Co-Founder, Chairman & Editor-in-Chief, BioCentury
Chris Cashman, CEO, Protez Pharmaceuticals
Steve Engen, President and Representative Director, Solasia
Atsushi Nagahisa, President and CEO, RaQualia Pharma, Inc
|
| 6:00 pm |
Rhoto Cocktail Reception
|
| |
|
| |
| Part Two: Tuesday, November 10 - 9:00 a.m. - 5:00 p.m. |
| |
The issues surrounding mergers and consolidation will be examined from multiple angles through presentations and panel discussions. Presenters will include executives from Big Pharma & Biotechs, seasoned investors and world-class analysts.
|
| |
Morning Sessions |
| 9:00 am |
Introduction - Trend in Partnering Scheme: Fill the Pipeline Gaps and Find the Innovative Target - Between High Risk and Certain Return |
| |
Kohei Ueda, Director, Research Information & Alliance (RIA)
Strategic Research Planning Department, Pharmaceutical Research Division, Takeda Pharmaceuticals
|
| 9:30 am |
The Economics of Consolidation
|
| |
David Flores, Co-Founder, President & CEO, BioCentury
interview:
Koichi Kato, Senior Director, Licensing and External Research, Merck Banyu Pharmaceutical Co., Ltd. and
Patrick Keohane, Head of R&D Japan, Astra Zeneca
Ichiro Nakatomi, President & CEO, Nanocarrier
|
| 11:00 am |
Case Studies—Acquisitions |
| |
(Protez by Novartis): Chris Cashman, CEO, Protez Pharmaceuticals
(BioRexis by Pfizer): David King, Venture Partner, Quaker BioVentures
(Genentech by Roche): Joe McCracken, Vice President of Business Development, Genentech
|
| 12:30 pm |
Lunch |
| |
|
| |
Afternoon Sessions |
| 1:45 pm |
Key Issues in Merger & Acquisition Negotiations |
| |
Kazuki Kusaka, Managing Director, Lazard Frere KK
Gregory R. Salathe, Partner, Morgan Lewis, Tokyo
Shinichi Tamura, President and CEO, Sosei
|
| 3:25 pm |
Summary |
| |
Reed Maurer, Chairman, aRigen Pharmaceuticals
|
|
|
|
|
Union League of Philadelphia
www.unionleague.org
140 South Broad Street
Philadelphia, PA 19102-3003
(215) 563-6500
|
Japan America Society
of Greater Philadelphia
200 South Broad Street
Suite 700
Philadelphia, PA 19102
Tel: (215) 790-3810
Fax: (215) 790-3805
Email: jasgp@philachamber.com |
| |
This program was made possible in part by funding from the Commonwealth of PA's Department of Community and Economic Development.
|
| 2009 Sponsors |
Sister City Supporter
Airline Sponsors
|
|
